Study on ERCC1,XPD and XPA polymorphisms for prediction of platinum-based chemotherapy sensitivity in non-small cell lung cancer

OBJECTIVE:To analyze the correlations between genetic polymorphisms of ERCC1Asn118Asn,XPD Lys751Gln,XPA A23G and the clinical benefits to the platinum-based chemotherapy in NSCLC,and further investigate the effect of different genotypes for the survival and clinical outcome.METHODS:The polymerase chain reaction-restrictive fragment length polymorphism(PCR-RFLP)method was applied to measure the genotype in 94 patients with NSCLC,and the correlations of genetic polymorphisms with clinical benefits and survival were analyzed.RESULTS:The distributions of XPD genotypes differed significantly in median survival time(MST)(χ2=7.353,P=0.007),Lys/Lys was 11 months,while Lys/Gln and Gln/Gln was 12 months(95%CI:9.94-12.06,11.21-12.79,respectively),but there were no significant differences in clinical benefits to platinum-based chemotherapy,χ2=2.604,P=0.272.The same statistical results were found between the genetic polymorphisms and clinical benefits on ERCC1Asn118Asn and XPA A23G(χ2=0.451,P=1.000;χ2=1.383,P=0.550;respectively).The heterozygous genotypes of XPA and ERCC1 were not detected.CONCLUSION:XPD Lys751Gln genetic polymorphisms may be an important marker for prediction the survival in NSCLC,and can provide theoretical basis for individualized treatment.